Compendium of Cancer Genome Aberrations

Changes

Testpage5 (view source)

Revision as of 15:04, 12 December 2023

601 bytes removed ,  15:04, 12 December 2023
no edit summary
Line 1: Line 1: −
{{Under Construction}}
   
==Primary Author(s)*==
 
==Primary Author(s)*==
   Line 10: Line 9:  
==Cancer Category/Type==
 
==Cancer Category/Type==
   −
[[Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]]
+
[[HAEM4:Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]]
    
==Cancer Sub-Classification / Subtype==
 
==Cancer Sub-Classification / Subtype==
Line 96: Line 95:  
==Chromosomal Rearrangements (Gene Fusions)==
 
==Chromosomal Rearrangements (Gene Fusions)==
   −
{| class="wikitable sortable"
  −
|-
  −
!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Reference
  −
|-
  −
|t(5;9)(q33;q22)||''ITK'' / ''SYK''||der(5); der(9)||<ref>{{Cite journal|last=B|first=Streubel|last2=U|first2=Vinatzer|last3=M|first3=Willheim|last4=M|first4=Raderer|last5=A|first5=Chott|date=2006|title=Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/16341044/|language=en|pmid=16341044}}</ref><ref name=":4">{{Cite journal|last=M|first=Wang|last2=S|first2=Zhang|last3=Ss|first3=Chuang|last4=M|first4=Ashton-Key|last5=E|first5=Ochoa|last6=N|first6=Bolli|last7=G|first7=Vassiliou|last8=Z|first8=Gao|last9=Mq|first9=Du|date=2017|title=Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling|url=https://pubmed.ncbi.nlm.nih.gov/28148900/|language=en|doi=10.18632/oncotarget.14846|pmc=PMC5392284|pmid=28148900}}</ref>
  −
|-
  −
|t(7;14)(q35;q32.1)
  −
|''TRB/TCL1A''
  −
|der(7); der(14)
  −
|<ref>{{Cite journal|last=Mf|first=Cosimi|last2=I|first2=Casagranda|last3=G|first3=Ghiazza|last4=G|first4=Rossi|last5=P|first5=Galvani|date=1990|title=Rearrangements on chromosomes 7 and 14 with breakpoints at 7q35 and 14q11 in angioimmunoblastic lymphadenopathy and IBL-like T-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/2284141/|language=en|pmid=2284141}}</ref>
  −
|-
  −
|t(14;14)(q11;q32.1) / inv(14)(q11q32.1)
  −
|''TRA-TRD/TCL1A''
  −
|der(14)
  −
|<ref>{{Cite journal|last=B|first=Schlegelberger|last2=A|first2=Feller|last3=A|first3=Himmler|last4=W|first4=Grote|date=1990|title=Inv(14)(q11q32) in one of four different clones in a case of angioimmunoblastic lymphadenopathy|url=https://pubmed.ncbi.nlm.nih.gov/2293883/|language=en|pmid=2293883}}</ref><ref>{{Cite journal|last=E|first=Leich|last2=E|first2=Haralambieva|last3=A|first3=Zettl|last4=A|first4=Chott|last5=T|first5=Rüdiger|last6=S|first6=Höller|last7=Hk|first7=Müller-Hermelink|last8=G|first8=Ott|last9=A|first9=Rosenwald|date=2007|title=Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas|url=https://pubmed.ncbi.nlm.nih.gov/17582237/|language=en|pmid=17582237}}</ref>
  −
|-
  −
|chr(2)(q33.2)
  −
|''CTLA4/CD28''
  −
|der(2)
  −
|<ref>{{Cite journal|last=Hy|first=Yoo|last2=P|first2=Kim|last3=Ws|first3=Kim|last4=Sh|first4=Lee|last5=S|first5=Kim|last6=Sy|first6=Kang|last7=Hy|first7=Jang|last8=Je|first8=Lee|last9=J|first9=Kim|date=2016|title=Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/26819049/|language=en|doi=10.3324/haematol.2015.139253|pmc=PMC5013939|pmid=26819049}}</ref>
  −
|}
  −
   
==Characteristic Chromosomal Aberrations / Patterns==
 
==Characteristic Chromosomal Aberrations / Patterns==
   Line 223: Line 200:  
**''TET2'' (50-80%)
 
**''TET2'' (50-80%)
 
**''DNMT3A'' (20-30%)
 
**''DNMT3A'' (20-30%)
 +
 +
==Genes and Main Pathways Involved==
 +
{| class="wikitable"
 +
|+
 +
!Molecular Features
 +
!Pathway
 +
!Pathophysiologic Outcome
 +
|-
 +
|''FYN'', ''PLCG1'', and ''CD28'' mutations
 +
|T-cell receptor signaling pathway<ref name=":4" /><ref name=":6" /><ref name=":3" /><ref name=":13" />
 +
|Increased proliferation and survival
 +
|-
 +
|''IDH2'', ''TET2'', and ''DNMT3A'' mutations
 +
|Histone modification and chromatin remodeling<ref name=":4" /><ref name=":5" /><ref name=":11" /><ref name=":12" />
 +
|Abnormal gene expression program
 +
|}
 +
 +
*
    
==Diagnostic Testing Methods==
 
==Diagnostic Testing Methods==
Line 229: Line 224:  
*''IDH2'' R172 mutations are specific to AITL
 
*''IDH2'' R172 mutations are specific to AITL
 
*T-Cell receptor and immunoglobulin genes rearrangement detection by karyotyping and FISH analysis
 
*T-Cell receptor and immunoglobulin genes rearrangement detection by karyotyping and FISH analysis
 +
 +
==Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)==
 +
 +
*Overall prognosis is poor<ref name=":9">{{Cite journal|last=N|first=Mourad|last2=N|first2=Mounier|last3=J|first3=Brière|last4=E|first4=Raffoux|last5=A|first5=Delmer|last6=A|first6=Feller|last7=Cj|first7=Meijer|last8=Jf|first8=Emile|last9=R|first9=Bouabdallah|date=2008|title=Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials|url=https://pubmed.ncbi.nlm.nih.gov/18292286/|language=en|doi=10.1182/blood-2007-08-105759|pmc=PMC2343588|pmid=18292286}}</ref><ref name=":10">{{Cite journal|last=J|first=Vose|last2=J|first2=Armitage|last3=D|first3=Weisenburger|date=2008|title=International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes|url=https://pubmed.ncbi.nlm.nih.gov/18626005/|language=en|pmid=18626005}}</ref>
 +
*Median survival < 3 years, even with aggressive treatment<ref name=":9" /><ref name=":10" />
 +
*Male sex, mediastinal lymphadenopathy, and anemia adversely affect the survival<ref name=":9" />
    
'''Suggested Treatment Regimens based on NCCN Guideline Version 1.2020 (TCEL-B 3 of 5)'''
 
'''Suggested Treatment Regimens based on NCCN Guideline Version 1.2020 (TCEL-B 3 of 5)'''
Line 278: Line 279:  
==Links==
 
==Links==
   −
[[Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]]
+
[[HAEM4:Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]]
 +
 
 
==References==
 
==References==
 
(use "Cite" icon at top of page)
 
(use "Cite" icon at top of page)
 
<references />
 
<references />
 +
===EXAMPLE Book===
 +
 +
#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.
    
==Notes==
 
==Notes==
 
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.
 
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/8794...13640"